JP2010528002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528002A5 JP2010528002A5 JP2010509325A JP2010509325A JP2010528002A5 JP 2010528002 A5 JP2010528002 A5 JP 2010528002A5 JP 2010509325 A JP2010509325 A JP 2010509325A JP 2010509325 A JP2010509325 A JP 2010509325A JP 2010528002 A5 JP2010528002 A5 JP 2010528002A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- therapeutic agent
- sost
- bone
- fab fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims description 10
- 230000011164 ossification Effects 0.000 claims description 10
- 101150098533 SOST gene Proteins 0.000 claims description 9
- 102100034201 Sclerostin Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 230000004927 fusion Effects 0.000 claims description 6
- 230000008468 bone growth Effects 0.000 claims description 5
- 206010017076 Fracture Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 208000010392 Bone Fractures Diseases 0.000 claims description 3
- 230000000399 orthopedic effect Effects 0.000 claims description 3
- 230000003239 periodontal effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 102000058171 human SOST Human genes 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 102000019307 Sclerostin Human genes 0.000 description 6
- 108050006698 Sclerostin Proteins 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 108010043958 Peptoids Proteins 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 208000029725 Metabolic bone disease Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004171 Cathepsin K Human genes 0.000 description 1
- 108090000625 Cathepsin K Proteins 0.000 description 1
- 208000013558 Developmental Bone disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010049811 Extraskeletal ossification Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000034970 Heterotopic Ossification Diseases 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101100421899 Mus musculus Sost gene Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000009469 Ossification of Posterior Longitudinal Ligament Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 208000008558 Osteophyte Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 201000010934 exostosis Diseases 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004446 longitudinal ligament Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88264206P | 2006-12-29 | 2006-12-29 | |
| PCT/US2007/088542 WO2009131553A2 (en) | 2006-12-29 | 2007-12-21 | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013255627A Division JP2014074046A (ja) | 2006-12-29 | 2013-12-11 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010528002A JP2010528002A (ja) | 2010-08-19 |
| JP2010528002A5 true JP2010528002A5 (enExample) | 2014-03-06 |
Family
ID=39584303
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509325A Withdrawn JP2010528002A (ja) | 2006-12-29 | 2007-12-21 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2013255627A Withdrawn JP2014074046A (ja) | 2006-12-29 | 2013-12-11 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2016161654A Withdrawn JP2017014263A (ja) | 2006-12-29 | 2016-08-22 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2018179643A Pending JP2018199725A (ja) | 2006-12-29 | 2018-09-26 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013255627A Withdrawn JP2014074046A (ja) | 2006-12-29 | 2013-12-11 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2016161654A Withdrawn JP2017014263A (ja) | 2006-12-29 | 2016-08-22 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
| JP2018179643A Pending JP2018199725A (ja) | 2006-12-29 | 2018-09-26 | Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US8178099B2 (enExample) |
| EP (3) | EP2144613B1 (enExample) |
| JP (4) | JP2010528002A (enExample) |
| DK (1) | DK3345607T3 (enExample) |
| ES (2) | ES2666650T3 (enExample) |
| FI (1) | FI3345607T3 (enExample) |
| HU (1) | HUE060822T2 (enExample) |
| LT (1) | LT3345607T (enExample) |
| PL (1) | PL3345607T3 (enExample) |
| PT (1) | PT3345607T (enExample) |
| SI (1) | SI3345607T1 (enExample) |
| WO (1) | WO2009131553A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2272093T5 (es) | 1998-11-27 | 2016-06-21 | Ucb Pharma S.A. | Composiciones y métodos para incrementar la mineralización de la substancia ósea |
| US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) * | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| JP2008511420A (ja) | 2004-08-30 | 2008-04-17 | スピネオベイションズ・インコポレーテッド | 脊髄の椎間板内障害の治療の方法 |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| EP2144613B1 (en) * | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| JP5583591B2 (ja) | 2007-11-21 | 2014-09-03 | アムジエン・インコーポレーテツド | Ｗｉｓｅ結合抗体及びエピトープ |
| US8469961B2 (en) * | 2008-03-05 | 2013-06-25 | Neville Alleyne | Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints |
| WO2010115932A1 (en) * | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| JP2013525294A (ja) * | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | インプラント骨結合を改善するための方法および組成物 |
| SMT202000095T1 (it) | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| WO2012028683A1 (en) | 2010-09-02 | 2012-03-08 | Novartis Ag | Antibody gel system for sustained drug delivery |
| AU2012223358A1 (en) | 2011-03-01 | 2013-09-05 | Amgen Inc. | Sclerostin and DKK-1 bispecific binding agents |
| EP2688910B1 (en) | 2011-03-25 | 2019-05-29 | Amgen Inc. | Anti-sclerostin antibody crystals and formulations thereof |
| WO2013019954A1 (en) | 2011-08-04 | 2013-02-07 | Amgen Inc. | Method for treating bone gap defects |
| CA2858974A1 (en) | 2011-12-28 | 2013-07-04 | Amgen Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| WO2014006100A1 (en) | 2012-07-05 | 2014-01-09 | Ucb Pharma S.A. | Treatment for bone diseases |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9770415B2 (en) * | 2012-11-27 | 2017-09-26 | Southwest Research Institute | Delivery substrates from aligned polymer biomaterials for tissue repair |
| CN105073195A (zh) * | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| MX382085B (es) | 2015-01-16 | 2025-03-13 | Spineovations Inc | Método de tratamiento de disco intervertebral |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| CN106202901A (zh) * | 2016-07-04 | 2016-12-07 | 奥美之路(北京)健康科技股份有限公司 | 骨龄远程在线判读系统 |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| EP3754021A4 (en) | 2018-02-12 | 2021-11-10 | Aptacure Therapeutics Limited | SCLEROSTINE APTAMER AND ITS USE |
| CN119241705A (zh) | 2018-03-30 | 2025-01-03 | 安姆根有限公司 | C末端抗体变体 |
| US20220133957A1 (en) * | 2019-02-04 | 2022-05-05 | Emory University | Sclerostin Inhibitors That Promote Bone Morphogenetic Protein Expression |
| JP7572668B2 (ja) * | 2019-07-12 | 2024-10-24 | 国立大学法人京都大学 | 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体 |
| CN111658821A (zh) * | 2020-06-03 | 2020-09-15 | 深圳市百吉因生物科技有限公司 | 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用 |
| AU2024279691A1 (en) | 2023-06-02 | 2026-01-08 | 33 Medical, Inc. | Compositions for treatment of discogenic pain, and processes for making and using the same |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981002911A1 (en) | 1980-04-07 | 1981-10-15 | J Berman | Window shade roller assembly |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| ATE66608T1 (de) * | 1984-04-30 | 1991-09-15 | Procter & Gamble | Ausruestung fuer die behandlung der osteoporose. |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5324819A (en) | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
| US5344654A (en) | 1988-04-08 | 1994-09-06 | Stryker Corporation | Prosthetic devices having enhanced osteogenic properties |
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| US5298852A (en) | 1988-12-22 | 1994-03-29 | Robert Bosch Gmbh | Arrangement for and method of controlling a three-phase-generator in a vehicle |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5561173A (en) * | 1990-06-19 | 1996-10-01 | Carolyn M. Dry | Self-repairing, reinforced matrix materials |
| ES2204890T3 (es) | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
| US5656593A (en) | 1991-03-11 | 1997-08-12 | Creative Biomolecules, Inc. | Morphogen induced periodontal tissue regeneration |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| WO1993009229A1 (en) | 1991-11-04 | 1993-05-13 | Genetics Institute, Inc. | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| GB9125979D0 (en) | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
| DE69321218T2 (de) | 1992-02-19 | 1999-02-18 | Schering Corp., Kenilworth, N.J. | Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4 |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| EP0679097B1 (en) * | 1993-01-12 | 1997-05-28 | Genentech, Inc. | Tgf-beta formulation for inducing bone growth |
| TW303299B (enExample) * | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
| US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US5550134A (en) * | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
| DE19647853A1 (de) * | 1996-11-19 | 1998-05-20 | Bioph Biotech Entw Pharm Gmbh | Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität |
| US5939039A (en) | 1997-01-16 | 1999-08-17 | Orthovita, Inc. | Methods for production of calcium phosphate |
| ATE239514T1 (de) | 1997-02-07 | 2003-05-15 | Stryker Corp | Matrixlose osteogene vorrichtungen und implantate und verfahren zu deren verwendung |
| US20020098222A1 (en) * | 1997-03-13 | 2002-07-25 | John F. Wironen | Bone paste |
| US7041641B2 (en) | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
| JP2001524000A (ja) * | 1997-04-22 | 2001-11-27 | ワシントン リサーチ ファンデーション | Ｔｒａｐ被覆骨移植片及びプロテーゼ |
| US6025538A (en) | 1998-11-20 | 2000-02-15 | Musculoskeletal Transplant Foundation | Compound bone structure fabricated from allograft tissue |
| ES2272093T5 (es) | 1998-11-27 | 2016-06-21 | Ucb Pharma S.A. | Composiciones y métodos para incrementar la mineralización de la substancia ósea |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US6756480B2 (en) * | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| US20030082233A1 (en) | 2000-12-01 | 2003-05-01 | Lyons Karen M. | Method and composition for modulating bone growth |
| US20020169122A1 (en) | 2001-02-23 | 2002-11-14 | Wyeth | Chondrogenic potential of human bone marrow-derived CD105+ cells by BMP |
| US6949251B2 (en) | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
| WO2002092764A2 (en) | 2001-05-11 | 2002-11-21 | Wyeth | Transgenic animal model of bone mass modulation |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| PT2295081T (pt) * | 2001-06-26 | 2019-02-01 | Amgen Inc | Anticorpos contra opgl |
| CN100515504C (zh) | 2001-10-12 | 2009-07-22 | 美国英佛曼公司 | 涂层,涂布体及其制造方法 |
| CA2465499A1 (en) * | 2001-11-08 | 2003-05-15 | Merck & Co., Inc. | Compositions and methods for treating osteoporosis |
| CA2472472A1 (en) * | 2002-01-10 | 2003-07-24 | Osteotrophin Llc | Treatment of bone disorders with skeletal anabolic drugs |
| CN1622826A (zh) * | 2002-01-17 | 2005-06-01 | 德克萨斯系统大学董事会 | 用凝血酶肽衍生物刺激骨生长和软骨形成 |
| JP3646167B2 (ja) | 2002-02-19 | 2005-05-11 | 独立行政法人産業技術総合研究所 | フォスフォフォリンを含む複合生体材料 |
| US7332276B2 (en) * | 2002-03-01 | 2008-02-19 | Celltech R&D, Inc. | Methods to increase or decrease bone density |
| US7166133B2 (en) * | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
| US20040023356A1 (en) | 2002-06-14 | 2004-02-05 | Robb Krumlauf | Wise/Sost nucleic acid sequences and amino acid sequences |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US20040002770A1 (en) | 2002-06-28 | 2004-01-01 | King Richard S. | Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof |
| NZ537610A (en) * | 2002-07-02 | 2006-07-28 | Smithkline Beecham Corp | Stable formulations of the C242 antibody |
| US20040023322A1 (en) * | 2002-08-01 | 2004-02-05 | Goodheart Clyde R. | Method of producing non-recombinant BMP-2 and use thereof |
| KR20040023356A (ko) | 2002-09-11 | 2004-03-18 | 현대모비스 주식회사 | 파킹브레이크 작동시 출발제한 시스템 및 그 방법 |
| AU2002335562B2 (en) | 2002-09-30 | 2007-07-05 | Regen Biotech, Inc. | Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers |
| JP3851602B2 (ja) * | 2002-10-02 | 2006-11-29 | ペンタックス株式会社 | 骨形成治療デバイス |
| WO2005028678A2 (en) | 2003-06-06 | 2005-03-31 | Wyeth | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby |
| CA2529623A1 (en) | 2003-06-16 | 2005-02-17 | Celltech R & D, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US7943393B2 (en) | 2003-07-14 | 2011-05-17 | Phynexus, Inc. | Method and device for extracting an analyte |
| US6976816B2 (en) | 2003-08-01 | 2005-12-20 | Dana Corporation | Combination lock washer and spindle bearing assembly |
| MY141763A (en) * | 2003-09-18 | 2010-06-30 | Novartis Ag | Pharmaceutical products comprising bisphosphonates |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8895540B2 (en) * | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| WO2005070439A1 (en) * | 2004-01-09 | 2005-08-04 | Regeneration Technologies Inc. | Implant comprising a human muscle tissue matrix |
| US7189263B2 (en) | 2004-02-03 | 2007-03-13 | Vita Special Purpose Corporation | Biocompatible bone graft material |
| US7531518B2 (en) | 2004-05-14 | 2009-05-12 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US7648965B2 (en) | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| JP2008509087A (ja) * | 2004-05-27 | 2008-03-27 | アクセルロン ファーマ インコーポレーテッド | Ｔｇｆ抑制解除因子およびそれに関連する使用方法 |
| MX2007001221A (es) | 2004-08-04 | 2007-03-23 | Amgen Inc | Anticuerpos para proteina dickkopf-1 (dkk-1). |
| JP2008517660A (ja) * | 2004-10-22 | 2008-05-29 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 生物剤を送達する中空かつ多孔質の整形外科用または歯科用のインプラント |
| US20060148704A1 (en) * | 2005-01-06 | 2006-07-06 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| US7531533B2 (en) * | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
| US8071574B2 (en) | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
| US20060198863A1 (en) | 2005-03-03 | 2006-09-07 | Musculoskeletal Transplant Foundation | Ceramic composition for filling bone defects |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| JP2006320442A (ja) | 2005-05-18 | 2006-11-30 | Toshiba Ceramics Co Ltd | リン酸カルシウム系骨補填材 |
| US20060293667A1 (en) | 2005-05-19 | 2006-12-28 | Agnes Vignery | Bone implant device and methods of using same |
| WO2006135734A2 (en) | 2005-06-10 | 2006-12-21 | The Regents Of The University Of California | Compositions and methods for altering bone density and bone patterning |
| KR20080019249A (ko) * | 2005-06-15 | 2008-03-03 | 쉐링 코포레이션 | 안정한 항체 제형 |
| WO2007030616A2 (en) | 2005-09-09 | 2007-03-15 | Wright Medical Technology, Inc. | Composite bone graft substitute cement and articles produced therefrom |
| CA2630077C (en) | 2005-11-17 | 2014-07-15 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2007076062A2 (en) | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| EP2460828A3 (en) | 2006-11-10 | 2012-08-08 | UCB Pharma, S.A. | Antibodies and diagnostics |
| EP2144613B1 (en) * | 2006-12-29 | 2018-03-21 | OstéoQC Inc. | Methods of altering bone growth by administration of sost or wise antagonist or agonist |
| JP2010524846A (ja) | 2007-03-20 | 2010-07-22 | イーライ リリー アンド カンパニー | 抗スクレロスチン抗体 |
| CN101663043B (zh) | 2007-04-27 | 2014-03-12 | 尤尼基因实验室公司 | 促进和保持骨生长的方法和组合物 |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| HRP20180421T1 (hr) * | 2010-11-17 | 2018-04-20 | Chugai Seiyaku Kabushiki Kaisha | Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JP6511233B2 (ja) | 2014-08-28 | 2019-05-15 | 株式会社竹中工務店 | 柱脚部と鉄骨梁との接合構造 |
-
2007
- 2007-12-21 EP EP07875255.7A patent/EP2144613B1/en not_active Revoked
- 2007-12-21 ES ES07875255.7T patent/ES2666650T3/es active Active
- 2007-12-21 ES ES18157578T patent/ES2930183T3/es active Active
- 2007-12-21 EP EP18157578.8A patent/EP3345607B1/en not_active Revoked
- 2007-12-21 JP JP2010509325A patent/JP2010528002A/ja not_active Withdrawn
- 2007-12-21 HU HUE18157578A patent/HUE060822T2/hu unknown
- 2007-12-21 PT PT181575788T patent/PT3345607T/pt unknown
- 2007-12-21 EP EP22200370.9A patent/EP4176884A1/en active Pending
- 2007-12-21 PL PL18157578.8T patent/PL3345607T3/pl unknown
- 2007-12-21 DK DK18157578.8T patent/DK3345607T3/da active
- 2007-12-21 SI SI200732194T patent/SI3345607T1/sl unknown
- 2007-12-21 FI FIEP18157578.8T patent/FI3345607T3/fi active
- 2007-12-21 WO PCT/US2007/088542 patent/WO2009131553A2/en not_active Ceased
- 2007-12-21 LT LTEP18157578.8T patent/LT3345607T/lt unknown
- 2007-12-21 US US11/962,522 patent/US8178099B2/en active Active
-
2012
- 2012-03-15 US US13/420,846 patent/US20120201815A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/796,530 patent/US8877196B2/en active Active
- 2013-12-11 JP JP2013255627A patent/JP2014074046A/ja not_active Withdrawn
-
2014
- 2014-10-02 US US14/504,544 patent/US20150086571A1/en not_active Abandoned
-
2016
- 2016-08-22 JP JP2016161654A patent/JP2017014263A/ja not_active Withdrawn
- 2016-09-19 US US15/269,022 patent/US11608373B2/en active Active
-
2018
- 2018-09-26 JP JP2018179643A patent/JP2018199725A/ja active Pending
-
2023
- 2023-03-20 US US18/123,569 patent/US11807681B2/en active Active
- 2023-06-21 US US18/339,147 patent/US11891438B2/en active Active
- 2023-12-29 US US18/401,117 patent/US20240360207A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528002A5 (enExample) | ||
| Virdi et al. | Sclerostin antibody increases bone volume and enhances implant fixation in a rat model | |
| Herford et al. | Reconstruction of mandibular continuity defects with bone morphogenetic protein-2 (rhBMP-2) | |
| Vukicevic et al. | The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing | |
| US8075562B2 (en) | Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery | |
| US12264187B2 (en) | Compositions and methods for targeted therapeutic delivery to bone | |
| US9610320B2 (en) | Surgical applications for BMP binding protein | |
| US20150232558A1 (en) | Stimulating bone formation by inhibition of cd28 co-stimulation | |
| AU2007338627B2 (en) | Surgical applications for BMP binding protein | |
| US9694047B2 (en) | Enhancement of bone morphogenic protein (BMP) retention with BMP binding peptide (BBP) | |
| KR20150109386A (ko) | 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체 | |
| Cunningham et al. | Osseointegration of autograft versus osteogenic protein–1 in posterolateral spinal arthrodesis: emphasis on the comparative mechanisms of bone induction | |
| Tatsumi et al. | Effect of ageing on healing of bilateral mandibular condyle fractures in a rat model | |
| JP2008540328A (ja) | 脱灰骨基質（ｄｅｍｉｎｅｒａｌｉｚｅｄｂｏｎｅｍａｔｒｉｘ）の活性化抽出 | |
| KR20160032125A (ko) | 골 이식편의 골형성 잠재력 강화 | |
| Buma et al. | Changes in innervation of long bones after insertion of an implant: Immunocytochemical study in goats with antibodies to calcitonin gene‐related peptide and B‐50/GAP‐43 | |
| Vegger et al. | Systemic treatment with strontium ranelate does not influence the healing of femoral mid-shaft defects in rats | |
| Lin et al. | Combined antisclerostin antibody and parathyroid hormone (1–34) synergistically enhance the healing of bone defects in ovariectomized rats | |
| Torres et al. | The salivary peptide histatin-1 enhances bone repair in vivo | |
| US12496330B2 (en) | Methods of improving spinal fusion with abaloparatide | |
| Baral | Osseointegration of a Cementless Total Knee Arthroplasty in a Murine Model of Glucocorticoid Induced Osteoporosis | |
| Rittenberg et al. | BMP-induced heterotopic bone formation in fetuin-deficient mice | |
| Bobyn | Improving Outcomes in NF1 Spine Fusion | |
| Chen | Recombinant human morphogenetic protein: its future role in spinal fusions | |
| Curak | Slobodan Vukicevic, Hermann Oppermann, Donatella Verbanac, Morana Jankolija, Irena Popek, Jasna |